Study study type PathologyT1T0Patientssample sizesROB Results

la/mBC - HR-positive - 1st line (L1) breast cancer - HR positive la/mBC - HR positive la/mBC - HR-positive - 1st line (L1)

versus trastuzumab plus chemotherapy
trastuzumab plus endocrine therapy
SYSUCC-002, 2022
  NCT01950182
RCTla/mBC - HER2 positive - 1st Line (L1), la/mBC - HR-positive - 1st line (L1)trastuzumab plus endocrine therapytrastuzumab plus chemotherapyFemale patients aged of 18 or more, with locally histology confirmed mBC, HR-positive (ER and/or PR-positive) and HER2-positive196 / 196some concern
inconclusive
  • inconclusive 12 % decrease in progression or deaths (PFS) (PE)